CCDC33

Across TCGA pan-cancer cohorts, CCDC33 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCDC33 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CCDC33 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC33 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

ESCA, SARC, and STAD are the cancer types where CCDC33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.123	0.539	<.001	12	view →
SARC	DFS	Median	All	0.108	0.613	<.001	6	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	DFS	Median	All	0.309	0.606	.044	3	view →
SKCM	OS	Median	All	0.536	0.326	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCDC33–ESCA (DFS)

Open the ESCA breakdown →